​

Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?

OverviewForecastFinancialsChart

Dyne Therapeutics Ownership Summary

Dyne Therapeutics is owned by 110.60% institutional investors, 0.87% insiders. Blackrock is the largest institutional shareholder, holding 9.11% of DYN shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.35% of its assets in Dyne Therapeutics shares.

DYN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockDyne Therapeutics110.60%0.87%-11.48%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock7.39M9.11%$260.69M
Atlas venture life science advisors8.02M7.95%$188.94M
Fmr8.00M7.93%$188.41M
Blackrock funding, inc. /de7.95M7.88%$187.29M
Janus henderson group7.38M7.31%$173.81M
Vanguard group6.70M6.65%$157.94M
Ra capital management6.38M6.33%$150.34M
Fcpm iii services b.v.5.46M5.42%$128.70M
Rtw investments, lp5.22M5.17%$122.95M
State street3.72M3.68%$87.58M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Atlas venture life science advisors8.02M23.05%$188.94M
Fcpm iii services b.v.5.46M21.73%$128.70M
Mpm asset management682.38K12.92%$16.08M
Tcg crossover management2.65M6.10%$62.44M
Vr adviser2.17M3.51%$51.22M
Vivo capital1.11M2.94%$26.27M
Octagon capital advisors lp668.00K2.59%$15.74M
Ra capital management6.38M2.00%$150.34M
Rtw investments, lp5.22M1.86%$122.95M
Sofinnova investments1.07M1.84%$25.24M

Top Buyers

HolderShares% AssetsChange
Blackrock7.39M0.01%2.00M
Jefferies financial group1.80M0.25%1.80M
Norges bank950.10K0.00%950.10K
Point72 asset management924.68K0.05%822.20K
Braidwell lp681.18K0.48%681.18K

Top Sellers

HolderShares% AssetsChange
Rtw investments, lp5.22M1.86%-1.60M
Deep track capital, lp2.00M1.76%-1.28M
Fmr8.00M0.01%-1.03M
First light asset management420.43K0.95%-836.85K
Avoro capital advisors---650.00K

New Positions

HolderShares% AssetsChangeValue
Jefferies financial group1.80M0.25%1.80M$42.41M
Norges bank950.10K0.00%950.10K$22.38M
Braidwell lp681.18K0.48%681.18K$16.05M
Frontier capital management298.05K0.07%298.05K$7.02M
Cubist systematic strategies119.06K0.02%119.06K$2.81M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Headlands-1.00
Farther finance advisors-3.00
Allworth financial lp-5.00
Nelson, van denburg & campbell wealth management group-9.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2024204-1.45%111,580,268-0.38%1100.90%105-10.26%6214.81%
Sep 30, 20242075.08%111,994,7580.90%1110.59%117-7.14%5417.39%
Jun 30, 202419712.57%110,993,40616.43%1360.99%126-1.56%4658.62%
Mar 31, 202417528.68%95,333,55236.34%1170.91%12885.51%29-27.50%
Dec 31, 202313613.33%69,922,23416.75%1131.19%6916.95%4025.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF2.65M2.35%2.40K
Vanguard Total Stock Mkt Idx Inv2.63M2.33%-
iShares Russell 2000 ETF2.20M1.95%-19.09K
Fidelity Growth Compy Commingled Pl O1.79M1.78%348.61K
Fidelity Growth Compy Commingled Pl S1.84M1.62%2.40K
SPDR® S&P Biotech ETF1.81M1.60%-19.33K
Janus Henderson Global Life Sciences D1.72M1.52%305.02K
Janus Henderson Global Life Sciences1.41M1.39%-12.05K
Janus Henderson Glb Life Scn I2 USD1.46M1.29%80.51K
Fidelity Growth Company Fund1.30M1.15%-

Recent Insider Transactions

DateNameRoleActivityValue
Mar 13, 2025Friedl-Naderer Johanna Chief Commercial OfficerSell$1.73K
Mar 11, 2025Scalzo Richard William SVP, Head of Finance & Admin.Sell$15.28K
Mar 11, 2025Beskrovnaya Oxana Chief Scientific OfficerSell$24.50K
Mar 05, 2025Kerr Douglas Chief Medical OfficerSell$15.89K
Mar 05, 2025Cox John CEO & PresidentSell$48.04K

Insider Transactions Trends

DateBuySell
2025 Q1-9
2024 Q4-24
2024 Q3279
2024 Q2-26
2024 Q12122

DYN Ownership FAQ

Who Owns Dyne Therapeutics?

Dyne Therapeutics shareholders are primarily institutional investors at 110.60%, followed by 0.87% insiders and -11.47% retail investors. The average institutional ownership in Dyne Therapeutics's industry, Biotech Stocks , is 68.48%, which Dyne Therapeutics exceeds.

Who owns the most shares of Dyne Therapeutics?

Dyne Therapeutics’s largest shareholders are Blackrock (7.39M shares, 9.11%), Atlas venture life science advisors (8.02M shares, 7.95%), and Fmr (8M shares, 7.93%). Together, they hold 24.99% of Dyne Therapeutics’s total shares outstanding.

Does Blackrock own Dyne Therapeutics?

Yes, BlackRock owns 9.11% of Dyne Therapeutics, totaling 7.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 260.69M$. In the last quarter, BlackRock increased its holdings by 2M shares, a 37.05% change.

Who is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested, with 23.05% of its assets in 8.02M Dyne Therapeutics shares, valued at 188.94M$.

Who is the top mutual fund holder of Dyne Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Dyne Therapeutics shares, with 2.35% of its total shares outstanding invested in 2.65M Dyne Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools